Current treatment in advanced hepatocellular carcinoma and prospects for immuno-oncology therapy
10.3760/cma.j.issn.0253-3766.2017.08.001
- VernacularTitle: 晚期肝细胞癌治疗现状和免疫治疗新进展
- Author:
Jianming XU
1
Author Information
1. Department of Alimentary System Oncology, the 307th
- Publication Type:Review
- Keywords:
Neoplasms, hepatocellular;
Immuno-Oncology Therapy;
Immune Checkpoint Inhibitor
- From:
Chinese Journal of Oncology
2017;39(8):561-565
- CountryChina
- Language:Chinese
-
Abstract:
Treatment of patients with advanced hepatocellular carcinoma (HCC) remains a huge challenge since a widely accepted therapeutic strategy has not been identified. There are some special features in patients with HCC in China, such as are mainly related to hepatitis B virus infection, often diagnosed as advanced or end-stage disease, and usually have a poorer prognosis compared with patients in western countries. Hence, appropriate treatments are urgently needed for these patients. Notably, immune-oncology therapy has been received increased attention in recent years. Based on promising results observed in clinical trials, immune-oncology therapy has been approved for treatment of various malignant diseases and brings a new hope to the treatment of advanced HCC. The review summarizes the current situation of advanced HCC treatment in China and discusses the prospects of immuno-oncology therapy.
